WordNet

an abnormal new mass of tissue that serves no purpose (同)tumour, neoplasm
of or relating to the nervous and endocrine systems (especially as they function together)

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 肺外原発小細胞癌 extrapulmonary small cell cancer
2. 前立腺生検の解釈 interpretation of prostate biopsy
3. 前立腺癌治療中および治療後のフォローアップにおけるサーベイランス follow up surveillance during and after treatment for prostate cancer
4. 前立腺癌の危険因子 risk factors for prostate cancer
5. HIV感染と悪性腫瘍：マネージメント上の考慮事項 hiv infection and malignancy management considerations

miR-663 induces castration-resistant prostate cancer transformation and predicts clinical recurrence.

Jiao L1, Deng Z, Xu C, Yu Y, Li Y, Yang C, Chen J, Liu Z, Huang G, Li LC, Sun Y.
Journal of cellular physiology.J Cell Physiol.2014 Jul;229(7):834-44. doi: 10.1002/jcp.24510.
Castration-resistant prostate cancer (CRPC) and its treatment are challenging issues in prostate cancer management. Here, we report that miR-663 is upregulated in CRPC tissues. Overexpression of miR-663 in prostate LNCaP cells promotes cell proliferation and invasion, neuroendocrine differentiation,
PMID 24243035

Munshi PN1, Lubin M1, Bertino JR2.
The oncologist.Oncologist.2014 Jun 13. pii: theoncologist.2014-0178. [Epub ahead of print]
Sixty years ago, 6-thioguanine (6-TG) was introduced into the clinic. We suggest its full potential in therapy may not have been reached. In this paper, we contrast 6-TG and the more widely used 6-mercaptopurine; discuss 6-TG metabolism, pharmacokinetics, dosage and schedule; and summarize many of t
PMID 24928612

Spratt DE1, Gavane S, Tarlinton L, Fareedy SB, Doran MG, Zelefsky MJ, Osborne JR.
The Prostate.Prostate.2014 Jun 9. doi: 10.1002/pros.22831. [Epub ahead of print]
BACKGROUND: Fluorodeoxyglucose (FDG) positron emission tomography (PET) has well-characterized limitations in prostate adenocarcinoma (PCA). However, data assessing the utility of PET in neuroendocrine prostate cancer (NEPC) is limited to isolated case reports. Herein, we describe the first case ser
PMID 24913988

高田聡,吉川元清,細川幸成 [他],林美樹,藤本清秀,平尾佳彦
泌尿器科紀要 56(3), 173-175, 2010-03
… A computerized tomographyscan revealed a bladder tumor (cT3bN0M0), and urinarycy tologydemonstrated neuroendocrine carcinoma. … He underwent transurethral resection of bladder tumor and needle biopsyof the prostate. … Pathological examination demonstrated small cell carcinoma in the bladder tumor specimen and well differentiated adenocarcinoma (cT1c) with a Gleason score of 3＋4 in the prostatic specimen. …
NAID 120002036633

Cushing syndrome associated with prostatic tumor adrenocorticotropic hormone (ACTH) expression after maximal androgen blockade therapy

KATAOKA Kazuyoshi,AKASAKA Yoshikiyo,NAKAJIMA Kouichi,NAGAO Kouichi,HARA Hiroshi,MIURA Kazukiyo,ISHII Nobuhisa
International journal of urology 14(5), 436-439, 2007-05-01
NAID 10019495750

小杉道男,花輪靖雅,門間哲雄,斉藤史郎,廣瀬茂道
日本泌尿器科學會雜誌 94(4), 521-524, 2003-05-20
… 前立腺癌にみられるneuroendocrine(NE)differentiationは予後不良の因子とされ,ホルモン療法抵抗性で非常に進行が早いことが特徴であり,いまのところ有効な治療法は確立されていない.前立腺癌にNE differentiationがみられる頻度は,10%から92%までの報告がありその見解は一定しないが^<1)>,前立腺の純粋なNE carcinomaは非常にまれである.今回,前立腺腺癌と診断された後,ホルモン療法施行中に治療抵抗性となり,病状の急速な進行を …
NAID 110003060673